TDMS Study 89006-08 Pathology Tables
NTP Experiment-Test: 89006-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INTERFERON A/INTERFERON AD Date: 12/23/96
Route: SUBCUTANEOUS Time: 17:05:41
Facility: Southern Research Institute
Chemical CAS #: 76543-88-9
Lock Date: 09/03/93
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 89006-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INTERFERON A/INTERFERON AD Date: 12/23/96
Route: SUBCUTANEOUS Time: 17:05:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 500 U 5000 U 5000 U A
CONTROL A/D A/D
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 13 13 9 11
Natural Death 12 5 15 8
Dosing Accident 1
Survivors
Terminal Sacrifice 25 32 25 31
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (45) (50) (48) (49)
Intestine Large, Colon (47) (50) (50) (49)
Intestine Large, Cecum (48) (50) (50) (49)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Intestine Small, Duodenum (47) (50) (49) (45)
Intestine Small, Jejunum (47) (50) (49) (48)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Ileum (47) (50) (49) (48)
Histiocytic Sarcoma 1 (2%)
Liver (49) (50) (50) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Multiple 1 (2%) 1 (2%)
Hepatocellular Carcinoma 9 (18%) 10 (20%) 10 (20%) 12 (24%)
Hepatocellular Carcinoma, Multiple 7 (14%) 2 (4%) 3 (6%) 6 (12%)
Hepatocellular Adenoma 12 (24%) 16 (32%) 12 (24%) 13 (26%)
Hepatocellular Adenoma, Multiple 12 (24%) 9 (18%) 10 (20%) 9 (18%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Plasma Cell Tumor Malignant, Metastatic,
Spleen 1 (2%)
Mesentery (21) (21) (18) (16)
Carcinoma, Metastatic, Harderian Gland 1 (5%)
Fibrosarcoma 1 (6%)
Fibrosarcoma, Metastatic, Skin 1 (5%) 1 (6%)
Fibrosarcoma, Metastatic, Tissue NOS 1 (5%)
Hemangiosarcoma 1 (6%)
Page 2
NTP Experiment-Test: 89006-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INTERFERON A/INTERFERON AD Date: 12/23/96
Route: SUBCUTANEOUS Time: 17:05:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 500 U 5000 U 5000 U A
CONTROL A/D A/D
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Hepatocellular Carcinoma, Metastatic, Liver 1 (5%)
Histiocytic Sarcoma 1 (5%) 1 (5%)
Liposarcoma 1 (5%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (6%)
Pancreas (48) (50) (50) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Fibrosarcoma, Metastatic, Tissue NOS 1 (2%)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Acinus, Adenoma 1 (2%)
Salivary Glands (50) (50) (48) (49)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Stomach, Forestomach (48) (50) (50) (46)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Squamous Cell Papilloma 2 (4%)
Stomach, Glandular (48) (50) (50) (46)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (49) (50) (49)
Adenoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Capsule, Adenoma 1 (2%)
Adrenal Medulla (50) (49) (50) (49)
Pheochromocytoma Malignant 1 (2%) 1 (2%)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (48) (50) (50) (50)
Adenoma 1 (2%)
Pituitary Gland (46) (47) (44) (43)
Pars Distalis, Adenoma 11 (24%) 8 (17%) 7 (16%) 5 (12%)
Pars Intermedia, Adenoma 1 (2%)
Page 3
NTP Experiment-Test: 89006-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INTERFERON A/INTERFERON AD Date: 12/23/96
Route: SUBCUTANEOUS Time: 17:05:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 500 U 5000 U 5000 U A
CONTROL A/D A/D
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Thyroid Gland (50) (50) (49) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Follicular Cell, Adenoma 5 (10%) 3 (6%) 2 (4%) 4 (8%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (2) (1)
Fibrosarcoma, Metastatic, Skin 1 (50%)
Tissue NOS (1) (1) (2)
Abdominal, Fibrosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (48) (49) (47) (49)
Hemangioma 1 (2%)
Ovary (46) (48) (49) (48)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Cystadenoma 4 (9%) 2 (4%) 1 (2%)
Granulosa Cell Tumor Benign 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Teratoma Benign 1 (2%) 1 (2%)
Uterus (50) (50) (50) (50)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Endometrium, Polyp Stromal 1 (2%) 1 (2%) 2 (4%)
Endometrium, Sarcoma Stromal 1 (2%)
Vagina (48) (50) (47) (46)
Sarcoma 1 (2%)
Squamous Cell Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Plasma Cell Tumor Malignant, Metastatic,
Spleen 1 (2%)
Lymph Node (12) (13) (9) (11)
Bronchial, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (8%)
Iliac, Histiocytic Sarcoma 1 (8%) 1 (8%)
Inguinal, Mast Cell Tumor Malignant,
Metastatic, Uncertain Primary Site 1 (11%)
Page 4
NTP Experiment-Test: 89006-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INTERFERON A/INTERFERON AD Date: 12/23/96
Route: SUBCUTANEOUS Time: 17:05:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 500 U 5000 U 5000 U A
CONTROL A/D A/D
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Mediastinal, Carcinoma, Metastatic,
Harderian Gland 1 (8%)
Mediastinal, Fibrosarcoma, Metastatic,
Mesentery 1 (9%)
Mediastinal, Fibrosarcoma, Metastatic, Skin 1 (8%)
Mediastinal, Fibrosarcoma, Metastatic,
Tissue NOS 1 (8%)
Mediastinal, Hepatocellular Carcinoma,
Metastatic, Liver 1 (8%)
Mediastinal, Liposarcoma, Metastatic,
Mesentery 1 (8%)
Pancreatic, Histiocytic Sarcoma 1 (8%)
Renal, Histiocytic Sarcoma 1 (8%) 1 (11%)
Renal, Liposarcoma, Metastatic, Mesentery 1 (8%)
Lymph Node, Mandibular (49) (49) (47) (48)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Lymph Node, Mesenteric (45) (50) (50) (47)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Spleen (47) (50) (50) (49)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Plasma Cell Tumor Malignant 1 (2%)
Thymus (41) (48) (48) (39)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Histiocytic Sarcoma 1 (2%)
Liposarcoma, Metastatic, Mesentery 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (48) (50) (50)
Carcinoma 1 (2%)
Skin (50) (50) (50) (50)
Basal Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Page 5
NTP Experiment-Test: 89006-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INTERFERON A/INTERFERON AD Date: 12/23/96
Route: SUBCUTANEOUS Time: 17:05:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 500 U 5000 U 5000 U A
CONTROL A/D A/D
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Subcutaneous Tissue, Carcinoma, Metastatic,
Harderian Gland 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 2 (4%) 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 2 (4%) 2 (4%) 2 (4%)
Subcutaneous Tissue, Mast Cell Tumor
Malignant, Metastatic, Uncertain Primary
Site 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Osteosarcoma 1 (2%) 1 (2%)
Skeletal Muscle (50) (50) (50) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Fibrosarcoma, Metastatic, Tissue NOS 1 (2%)
Liposarcoma, Metastatic, Mesentery 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (49) (50) (50)
Spinal Cord (2) (2) (4) (1)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 5 (10%) 4 (8%) 3 (6%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 4 (8%) 7 (14%)
Basal Cell Carcinoma, Metastatic, Skin 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 2 (4%) 3 (6%) 4 (8%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Mediastinum, Mast Cell Tumor Malignant,
Metastatic, Uncertain Primary Site 1 (2%)
Nose (50) (50) (50) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Page 6
NTP Experiment-Test: 89006-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INTERFERON A/INTERFERON AD Date: 12/23/96
Route: SUBCUTANEOUS Time: 17:05:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 500 U 5000 U 5000 U A
CONTROL A/D A/D
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (8) (4) (3)
Adenoma 2 (67%) 5 (63%) 3 (75%) 3 (100%)
Carcinoma 1 (33%) 2 (25%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (48) (50) (49) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Ureter (1)
Fibrosarcoma, Metastatic, Skin 1 (100%)
Urinary Bladder (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%) 1 (2%) 2 (4%) 1 (2%)
Lymphoma Malignant 11 (22%) 13 (26%) 11 (22%) 6 (12%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 7
NTP Experiment-Test: 89006-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INTERFERON A/INTERFERON AD Date: 12/23/96
Route: SUBCUTANEOUS Time: 17:05:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 500 U 5000 U 5000 U A
CONTROL A/D A/D
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 48 48 44 44
Total Primary Neoplasms 96 92 72 84
Total Animals with Benign Neoplasms 34 32 33 31
Total Benign Neoplasms 53 52 42 43
Total Animals with Malignant Neoplasms 35 33 27 30
Total Malignant Neoplasms 43 40 30 41
Total Animals with Metastatic Neoplasms 7 6 4 7
Total Metastatic Neoplasm 36 12 17 12
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 8
NTP Experiment-Test: 89006-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INTERFERON A/INTERFERON AD Date: 12/23/96
Route: SUBCUTANEOUS Time: 17:05:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 500 U 5000 U 5000 U A
CONTROL A/D A/D
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 10 15 11 13
Moribund Sacrifice 13 7 10 10
Dosing Accident 1
Survivors
Terminal Sacrifice 27 28 28 27
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (45) (45) (48) (43)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Intestine Small, Duodenum (49) (47) (49) (50)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (49) (47) (49) (50)
Carcinoma 1 (2%) 1 (2%) 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Intestine Small, Ileum (49) (47) (49) (50)
Fibrous Histiocytoma 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Liver (50) (50) (50) (50)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Fibrous Histiocytoma 1 (2%)
Hemangioma, Multiple 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%) 2 (4%) 2 (4%)
Hemangiosarcoma, Multiple 3 (6%) 3 (6%) 2 (4%) 2 (4%)
Hepatoblastoma 2 (4%) 1 (2%) 1 (2%) 3 (6%)
Hepatocellular Carcinoma 10 (20%) 17 (34%) 10 (20%) 13 (26%)
Hepatocellular Carcinoma, Multiple 8 (16%) 6 (12%) 4 (8%) 6 (12%)
Hepatocellular Adenoma 11 (22%) 10 (20%) 11 (22%) 14 (28%)
Hepatocellular Adenoma, Multiple 3 (6%) 4 (8%) 5 (10%) 5 (10%)
Hepatocholangiocarcinoma 1 (2%) 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Mesentery (7) (5) (6) (9)
Fibrosarcoma 1 (17%)
Fibrous Histiocytoma 1 (20%) 1 (17%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (14%) 1 (17%) 1 (11%)
Histiocytic Sarcoma 1 (11%)
Pancreas (49) (49) (49) (49)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Page 9
NTP Experiment-Test: 89006-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INTERFERON A/INTERFERON AD Date: 12/23/96
Route: SUBCUTANEOUS Time: 17:05:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 500 U 5000 U 5000 U A
CONTROL A/D A/D
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%) 1 (2%)
Salivary Glands (50) (50) (49) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Stomach, Forestomach (50) (48) (49) (50)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (50) (48) (49) (50)
Adenoma 1 (2%)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Tooth (24) (14) (24) (20)
Odontoma 1 (4%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (49) (50) (49)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Bilateral, Capsule, Adenoma 1 (2%)
Capsule, Adenoma 1 (2%) 1 (2%) 3 (6%) 3 (6%)
Adrenal Medulla (49) (49) (50) (49)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Bilateral, Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (50) (48) (50) (50)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Thyroid Gland (50) (49) (50) (50)
Follicular Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
Tissue NOS (1) (2) (1) (1)
Hepatoblastoma, Metastatic, Liver 1 (100%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 89006-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INTERFERON A/INTERFERON AD Date: 12/23/96
Route: SUBCUTANEOUS Time: 17:05:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 500 U 5000 U 5000 U A
CONTROL A/D A/D
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Preputial Gland (50) (50) (50) (50)
Adenoma 1 (2%)
Prostate (49) (49) (50) (49)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Seminal Vesicle (50) (50) (50) (50)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Testes (50) (50) (50) (50)
Sertoli Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hemangiosarcoma 2 (4%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (3) (3) (6) (3)
Iliac, Fibrous Histiocytoma 1 (33%)
Mediastinal, Fibrosarcoma, Metastatic,
Mesentery 1 (17%)
Mediastinal, Fibrous Histiocytoma 1 (33%)
Mediastinal, Fibrous Histiocytoma,
Metastatic, Mesentery 1 (17%)
Mediastinal, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (33%) 1 (17%) 1 (33%)
Mediastinal, Histiocytic Sarcoma 1 (33%)
Pancreatic, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (33%)
Renal, Fibrous Histiocytoma 1 (33%)
Lymph Node, Mandibular (47) (46) (45) (45)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (50) (48) (46) (50)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Spleen (49) (49) (49) (50)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Fibrous Histiocytoma 1 (2%)
Hemangiosarcoma 5 (10%) 2 (4%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Thymus (38) (38) (35) (39)
Fibrous Histiocytoma 1 (3%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 89006-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INTERFERON A/INTERFERON AD Date: 12/23/96
Route: SUBCUTANEOUS Time: 17:05:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 500 U 5000 U 5000 U A
CONTROL A/D A/D
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (49) (50) (50)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Hepatoblastoma,
Metastatic, Liver 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (50) (50) (50) (50)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 8 (16%) 10 (20%) 8 (16%) 5 (10%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 4 (8%) 4 (8%) 3 (6%) 3 (6%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Fibrosarcoma, Metastatic, Mesentery 1 (2%)
Fibrous Histiocytoma 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%) 2 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 6 (12%) 10 (20%) 2 (4%) 7 (14%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Mediastinum, Fibrosarcoma, Metastatic,
Mesentery 1 (2%)
Mediastinum, Fibrous Histiocytoma,
Metastatic, Mesentery 1 (2%)
Mediastinum, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (2%)
Nose (50) (50) (50) (50)
Carcinoma, Metastatic, Harderian Gland 2 (4%)
____________________________________________________________________________________________________________________________________
Page 12
NTP Experiment-Test: 89006-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INTERFERON A/INTERFERON AD Date: 12/23/96
Route: SUBCUTANEOUS Time: 17:05:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 500 U 5000 U 5000 U A
CONTROL A/D A/D
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (6) (8) (4)
Adenoma 2 (50%) 5 (83%) 4 (50%) 3 (75%)
Carcinoma 2 (50%) 1 (17%) 1 (13%) 1 (25%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (49) (49) (50)
Fibrous Histiocytoma 1 (2%)
Hemangioma 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Urinary Bladder (49) (49) (50) (50)
Hemangioma 1 (2%)
Transitional Epithelium, Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Lymphoma Malignant 4 (8%) 2 (4%) 5 (10%) 2 (4%)
Mesothelioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 13
NTP Experiment-Test: 89006-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INTERFERON A/INTERFERON AD Date: 12/23/96
Route: SUBCUTANEOUS Time: 17:05:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 500 U 5000 U 5000 U A
CONTROL A/D A/D
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 42 40 41 47
Total Primary Neoplasms 66 94 75 70
Total Animals with Benign Neoplasms 22 26 28 29
Total Benign Neoplasms 29 38 39 34
Total Animals with Malignant Neoplasms 32 30 25 30
Total Malignant Neoplasms 37 56 36 36
Total Animals with Metastatic Neoplasms 10 10 5 11
Total Metastatic Neoplasm 26 10 24 22
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 14
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------